Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Eisai Buys China Rights to GI Drug from Almirall

publication date: Apr 19, 2010
Eisai Co., Ltd., the fourth largest Japanese pharma, licensed the China rights to a gastroprokinetic agent, cinitapride tartrate, from Almirall, S.A. of Spain. Eisai obtained exclusive rights to develop, manufacture and market cinitapride in China. Eisai has a production facility in Suzhou. In 2001, Eisai bought the China rights to an antiallergic agent, Kestine, from Almirall. Terms of the new license were not disclosed. More details...


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China